Table 1.
Summary of the completed clinical trials of repurposed drugs for treatment of COVID-19.
| Sr. no | Drug name | Target/rationale for use | Clinical phase (sample size) | Findings | Status | Clinical trial identifier |
|---|---|---|---|---|---|---|
| 1. | Hydroxychloroquine | Block viral entry by inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidification. Additionally, may provide immunomodulatory effects through inhibition of cytokine production, autophagy, and lysosomal activity in host cell. |
Phase 3 (30) |
No Result Posted for this study | Completed | NCT04261517 |
| 2. | Lopinavir/ritonavir Ribavirin Interferon Beta-1B |
Protease Inhibitor | Phase II (127) |
No Result Posted for this study | Completed | NCT04276688 |
| 3. | Hydroxychloroquine Lopinavir/Ritonavir Interferon Beta-1A Interferon Beta-1B |
Protease Inhibitor |
Phase IV (60) |
No Result Posted for this study |
Completed | NCT04343768 |
| 4. | Baricitinib | Anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2 that inhibits JAK1- and JAK2-mediated cytokine release | Phase 2 & Phase 3 (12) |
No Result Posted for this study |
Completed | NCT04358614 |
| 5. | Ganovo Ritonavir Interferon nebulization |
Hepatitis C virus protease inhibitor | Phase IV (11) |
No Result Posted for this study |
Completed | NCT04291729 |
| 6. | Methylprednisolone | Immunomodulatory effect | Phase 2 & Phase 3 (80) |
No Result Posted for this study | Completed | NCT04244591 |